肺癌组织样本和血液样本EGFR基因检测对比研究

doi:10.3969/j.issn.1004-616x.2023.01.004

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (1): 21-25.doi: 10.3969/j.issn.1004-616x.2023.01.004

肺癌组织样本和血液样本EGFR基因检测对比研究

邓会岩¹, 刘畅¹, 贾迎¹, 李芳¹, 尹丹静¹, 檀紫瑞², 苏冰³, 刘月平¹

1. 河北医科大学第四医院病理科, 河北石家庄 050011;
2. 河北医科大学第四医院胸外科, 河北石家庄 050011;
3. 河北省宁晋县妇幼保健院, 河北邢台 055550

收稿日期:2022-04-20 修回日期:2022-12-31 发布日期:2023-02-09
通讯作者: 刘月平
作者简介:邓会岩,E-mail:denghuiyan_2000@163.com。
基金资助:
河北省卫生健康委医学科学研究课题计划项目(20230143)

Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples

DENG Huiyan¹, LIU Chang¹, JIA Ying¹, LI Fang¹, YIN Danjing¹, TAN Zirui², SU Bing³, LIU Yueping¹

1. Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
2. Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011;
3. Maternal and Child Health Hospital of Ningjin County, Xingtai 055550, Hebei, China

Received:2022-04-20 Revised:2022-12-31 Published:2023-02-09

摘要/Abstract

摘要： 目的: 研究肺腺癌患者不同样本EGFR基因检测结果的异同，以更精准地反映患者体内EGFR突变情况。方法: 收集2016年7月—2017年12月收治的Ⅲ~Ⅳ期经病理确诊为肺腺癌患者175例，175例均有血浆样本，其中119例同时有活检组织样本，12例同时有胸水沉渣细胞样本。采用突变扩增系统(ARMS)-聚合酶链式反应(PCR)方法对收集到的活检组织样本、胸水沉渣细胞样本和血液样本进行EGFR基因检测，分析不同类型样本间结果的差异，以及与患者临床病理指标的关系。结果: 联合检测的EGFR基因突变总阳性率较单纯血液样本阳性率提高了8.6%，较单纯组织样本提高了3.1%。EGFR突变在不同的性别(χ²=3.451，P=0.045)、肿瘤直径((χ²=8.911，P=0.002)、T分期((χ²=17.567，P=0.000)、淋巴结转移((χ²=18.511，P=0.000)、转移站数((χ²=3.341，P=0.047)和远处转移((χ²=10.874，P=0.001)组间的差异有统计学意义。将血液和组织两组样本EGFR突变率进行比较，差异有统计学意义(P=0.000)。在患者临床病理指标与生存时间的分析中，肿瘤直径[95%CI(0.151，0.725)，P=0.006]、淋巴结转移[95%CI(0.180，0.865)，P=0.020]、远处转移[95%CI(0.097，0.612)，P=0.003]均是影响患者无进展生存期的重要因素。结论: 肺癌患者血液样本、活检组织样本、胸水沉渣细胞样本在EGFR检测过程中的联合应用能够获得更高的检出率，可为临床更多地筛选出适合EGFR-酪氨酸激酶抑制剂(TKIs)治疗的人群。对于女性患者、肿瘤直径≥3 cm、T4期、淋巴结转移且超过3站、远处转移患者检测到血液EGFR基因突变的几率更高。其中肿瘤直径≥3 cm、淋巴结转移、远处转移患者的无进展生存期更短。

关键词: 肺腺癌, EGFR基因, 血液样本, 活检组织样本, 胸水沉渣细胞样本, 对比研究

Abstract: OBJECTIVE: To detect expression of the EGFR gene in lung adenocarcinomas so as to understand EGFR gene mutation in patients. METHODS: From July 1，2016 to December 1，2017，a total of 175 patients with stage III-IV lung adenocarcinomas who were admitted to our hospital were collected. Among them，all patients provided blood samples，119 provided tissue biopsy samples，175 provided plasma samples and 12 provided pleural fluid sediment cell samples. EGFR gene detection was performed on these samples using ARMS-PCR. Differences in results among the different types of samples and their relationships with patients' clinicopathological data were analyzed. RESULTS: Detection of EGFR gene expression was conducted on all blood and tissue samples. The total positive rate was 8.6% higher in the tissues than in that of blood samples and 3.1% higher than that in paraffin block tissues. EGFR mutation was found in different sex ((χ²=3.451，P=0.045)，tumor size ((χ²=8.911，P=0.002)，T stage ((χ²=17.567，P=0.000)，lymph node metastasis ((χ²=18.511，P=0.000)，metastasis station ((χ²=3.341，P=0.047) and distant metastasis ((χ²=10.874，P=0.001). EGFR mutation rates in blood and tissue samples were compared，and the difference was statistically significant (P=0.000). Tumor size [95%CI(0.151，0.725)，P=0.006]，lymph node metastases [95%CI(0.180，0.865)，P=0.020]，distant metastases [95%CI(0.097，0.612)，P=0.003] were important factors affecting progression-free survival. CONCLUSION: The combined application of samples from different tissues was useful in enhancing detection of EGFR gene expression. In addition，higher detection rate can increase the number of patients who are suitable for EGFR-tyrosine kinase inhibitors (TKIs) treatment in clinical practice. For female patients，the incidence of blood EGFR mutation was higher in those with tumor diameter ≥3 cm，stage T4，lymph node metastases with more than 3 stations，and distant metastases. Patients with tumor diameter ≥3 cm，lymph node metastasis and distant metastasis had shorter progression-free survival.

Key words: lung adenocarcinoma, EGFR gene, plasma samples, biopsy tissue samples, pleural fluid sediment cell samples, comparative study

中图分类号:

R365

邓会岩, 刘畅, 贾迎, 李芳, 尹丹静, 檀紫瑞, 苏冰, 刘月平. 肺癌组织样本和血液样本EGFR基因检测对比研究[J]. 癌变·畸变·突变, 2023, 35(1): 21-25.

DENG Huiyan, LIU Chang, JIA Ying, LI Fang, YIN Danjing, TAN Zirui, SU Bing, LIU Yueping. Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 21-25.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志:电子版, 2021, 13(3):63-69.
[3] 康丽菲, 郑杰, 朱翔. EGFR基因突变与肺腺癌主要病理分型及标本类型的关系[J]. 中国肺癌杂志, 2017, 20(6):382-388.
[4] WU Y L, ZHOU C C, HU C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6):an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2):213-222.
[5] RUSSO A, FRANCHINA T, RICCIARDI G R R, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC:where are we now and where are we going[J]. Crit Rev Oncol Hematol, 2017, 117:38-47.
[6] SUDA K, MURAKAMI I, SAKAI K, et al. Small cell lung cancer transformation and T790M mutation:complimentary roles in acquired resistance to kinase inhibitors in lung cancer[J]. Sci Rep, 2015, 5:14447.
[7] BARLESI F, MAZIERES J, MERLIO J P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer:results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)[J]. Lancet, 2016, 387(10026):1415-1426.
[8] WAN J C M, MASSIE C, GARCIA-CORBACHO J, et al. Liquid biopsies come of age:towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238.
[9] LYNCH T J, BELL D W, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350(21):2129-2139.
[10] 黄健, 王于理, 代平, 等. 胸水、血液EGFR基因突变检测在非小细胞肺癌治疗中的应用价值[J]. 山东医药, 2018, 58(6):61-63.
[11] 师艺, 马志萍, 崔文丽, 等. 肺腺癌活检组织、胸水及血液中表皮生长因子受体基因突变检测的比较分析[J]. 中华病理学杂志, 2018, 47(10):775-779.
[12] 王恩华, 朱明华, 步宏, 等. 非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J]. 中华病理学杂志, 2016, 45(2):73-77.
[13] LINDEMAN N I, CAGLE P T, AISNER D L, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors[J]. J Mol Diagn, 2018, 20(2):129-159.
[14] 陈一峰, 陈婷, 陈玮姗, 等. 胸水细胞蜡块在肺癌诊断和EGFR基因检测中的应用研究[J]. 中国现代医学杂志, 2018, 28(29):43-46.
[15] 李志阳, 张志杰, 谭小军, 等. 非小细胞肺癌患者表皮生长因子受体基因突变的异质性[J]. 实用医学杂志, 2017, 33(6):983-985.
[16] THRESS K S, BRANT R, CARR T H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma:a cross-platform comparison of leading technologies to support the clinical development of AZD9291[J]. Lung Cancer, 2015, 90(3):509-515.

肺癌组织样本和血液样本EGFR基因检测对比研究

Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	于运亮, 王莉莉, 李婷, 封建凯. 嘌呤能受体X1与肺腺癌预后及免疫细胞浸润的相关性研究[J]. 癌变·畸变·突变, 2022, 34(5): 353-360,365.
[2]	曾卓颖, 吴德生, 鲁晶晶, 廖慧, 赖洪飘, 袁建辉, 胡章立. 雌激素受体α介导氧化磷酸化通路在肺癌发生中的作用[J]. 癌变·畸变·突变, 2021, 33(4): 262-268.
[3]	杜强, 姚义勇, 曾刚. 基于TCGA数据库分析ASPM在肺腺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2020, 32(6): 457-463.
[4]	马阳, 吴娟, 纪晓坤, 王蕊, 杜芸, 王珩, 郭晓, 张艳. 沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响[J]. 癌变·畸变·突变, 2019, 31(5): 347-351,358.
[5]	李雨轩, 李凯, 张彤彤, 郭元彪, 殷俊, 包勇. 热休克蛋白HDJ1 影响肺腺癌细胞侵袭和迁移能力的研究[J]. 癌变·畸变·突变, 2017, 29(5): 358-363.
[6]	张　薇, 石玉枝, 霍建民. 肺腺癌及其转移淋巴结的基因表达谱研究[J]. 癌变·畸变·突变, 2006, 18(2): 105-107.
[7]	李　煜, 杨素霞, 周淑珍, 刘国廉. 保肺消瘤胶囊制剂抗肺癌的药效学研究[J]. 癌变·畸变·突变, 2004, 16(1): 33-35.